Published in Am J Pathol on December 01, 1993
Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A (1994) 4.33
Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am J Pathol (2004) 1.71
A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol (2009) 0.98
Alzheimer's disease: A hypothesis on pathogenesis. J Am Aging Assoc (2000) 0.81
Diffuse senile plaques: amorphous or fibrous? Am J Pathol (1995) 0.77
Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun (1984) 20.07
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (1987) 17.08
Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A (1985) 16.10
A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by beta protein immunostaining. Acta Neuropathol (1988) 4.10
Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci Lett (1989) 2.69
A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci (1987) 2.43
The occult aftermath of boxing. J Neurol Neurosurg Psychiatry (1990) 2.41
Ultrastructural localization of glial fibrillary acidic protein in mouse cerebellum by immunoperoxidase labeling. J Cell Biol (1977) 2.39
Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals. Neurosci Lett (1988) 2.26
Ultrastructural morphology of amyloid fibrils from neuritic and amyloid plaques. Acta Neuropathol (1983) 2.23
The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down's syndrome and Alzheimer's disease. Acta Neuropathol (1990) 2.23
A4 protein in Alzheimer's disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol (1989) 1.62
High-resolution electron microscopic analysis of the amyloid fibril in Alzheimer's disease. J Neuropathol Exp Neurol (1980) 1.59
Morphology and distribution of plaque and related deposits in the brains of Alzheimer's disease and control cases. An immunohistochemical study using amyloid beta-protein antibody. Lab Invest (1989) 1.56
A morphological analysis of senile plaques in the brains of non-demented persons of different ages using silver, immunocytochemical and lectin histochemical staining techniques. Neuropathol Appl Neurobiol (1990) 1.53
Electron micrograph of diffuse plaques. Initial stage of senile plaque formation in the Alzheimer brain. Am J Pathol (1989) 1.53
Diffusion artificats in 3,3'-diaminobenzidine cytochemistry. J Histochem Cytochem (1972) 1.47
Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. An immunoelectron microscopic study. Am J Pathol (1992) 1.37
Alzheimer patients and Down patients: cerebral preamyloid deposits differ ultrastructurally and histochemically from the amyloid of senile plaques. Neurosci Lett (1989) 1.35
Immunoelectron microscopic localization of amyloid beta protein in the diffuse plaques of Alzheimer-type dementia. Brain Res (1990) 1.23
Evidence of amyloid beta-protein immunoreactive early plaque lesions in Down's syndrome brains. Lab Invest (1989) 1.13
Ultrastructure of diffuse plaques in senile dementia of the Alzheimer type: comparison with primitive plaques. Acta Neuropathol (1991) 1.05
DAB cytochemistry: artifact problems in its current uses. J Histochem Cytochem (1980) 1.04
An analysis of the morphology of senile plaques in Down's syndrome patients of different ages using immunocytochemical and lectin histochemical techniques. Neuropathol Appl Neurobiol (1989) 0.99
Ultrastructural heterogeneity in cerebral amyloid of Alzheimer's disease. Acta Neuropathol (1988) 0.97
Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-beta protein monoclonal antibody. Lab Invest (1987) 0.93
Senile plaque-like structures: observation of a probably unknown type of senile plaque by periodic-acid methenamine silver (PAM) electron microscopy. Acta Neuropathol (1989) 0.90
Immunohistochemical and immunoelectron microscopical characterization of cerebrovascular and senile plaque amyloid in aged dogs' brains. Brain Res (1991) 0.87
Subpial beta/A4 amyloid deposition occurs between astroglial processes in Alzheimer-type dementia. Neurosci Lett (1991) 0.86
Relationship between non-fibrillary amyloid precursors and cell processes in the cortical neuropil of Alzheimer patients. Neurosci Lett (1991) 0.85
Ultrastructural localization of argyrophilic substances in diffuse plaques of Alzheimer-type dementia demonstrated by methenamine silver staining. Acta Neuropathol (1991) 0.83
Alzheimer patients: preamyloid deposits are immunoreactive with antibodies to extracellular domains of the amyloid precursor protein. Neurosci Lett (1991) 0.81
Light and electron microscopic examination of amyloid-rich primitive plaques: comparison with diffuse plaques. J Neurol (1990) 0.78
Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature (1990) 4.90
Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol (1995) 3.34
Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry (1990) 2.91
Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron (1995) 2.90
Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med (1996) 2.71
The neural cell adhesion molecule (NCAM) as a regulator of cell-cell interactions. Science (1988) 2.49
A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci (1987) 2.43
The neuropathology of Alzheimer's disease: a review with pathogenetic, aetiological and therapeutic considerations. Mech Ageing Dev (1985) 2.08
Effects of modifications of the RGD sequence and its context on recognition by the fibronectin receptor. J Biol Chem (1989) 2.00
A prospective, population-based study of the demographics, epidemiology, management, and outcome of out-of-hospital pediatric cardiopulmonary arrest. Ann Emerg Med (1999) 1.96
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol (1998) 1.93
Neuropsychological syndromes in presenile dementia due to cerebral atrophy. J Neurol Neurosurg Psychiatry (1986) 1.83
Progressive language disorder due to lobar atrophy. Ann Neurol (1992) 1.82
Apolipoprotein E4 and Alzheimer's disease pathology in Lewy body disease and in other beta-amyloid-forming diseases. Lancet (1994) 1.78
Changes in the monoamine containing neurones of the human CNS in senile dementia. Br J Psychiatry (1980) 1.74
Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest (1998) 1.70
Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol (2000) 1.66
Disease-specific patterns of locus coeruleus cell loss. Ann Neurol (1992) 1.64
Tau, ubiquitin, and alpha B-crystallin immunohistochemistry define the principal causes of degenerative frontotemporal dementia. Arch Neurol (1995) 1.59
Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem (1995) 1.56
Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry (1999) 1.55
Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol (1984) 1.47
Percutaneous pulmonary endoarterial biopsy in an experimental model of pulmonary hypertension. Chest (1998) 1.46
Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest (1997) 1.44
Polyploidy in the human nervous system. 1. The DNA content of neurones and glia of the cerebellum. J Neurol Sci (1973) 1.41
Lipoprotein pigments--their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. Brain (1974) 1.37
Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am J Pathol (1996) 1.36
Alzheimer's disease: a correlative study. J Neurol Neurosurg Psychiatry (1986) 1.36
The clinical pathological correlates of lobar atrophy. Dementia (1993) 1.31
The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. J Neuropathol Exp Neurol (1999) 1.31
Polyploidy in the human nervous system. 2. Studies of the glial cell populations of the Purkinje cell layer of the human cerebellum. J Neurol Sci (1973) 1.31
Some morphometric observations on the cerebral cortex and hippocampus in presenile Alzheimer's disease, senile dementia of Alzheimer type and Down's syndrome in middle age. J Neurol Sci (1985) 1.31
Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol (1999) 1.30
Correlation between senile plaque and neurofibrillary tangle counts in cerebral cortex and neuronal counts in cortex and subcortical structures in Alzheimer's disease. Neurosci Lett (1985) 1.22
The pathology of the human locus ceruleus. Clin Neuropathol (1983) 1.20
Classification and description of frontotemporal dementias. Ann N Y Acad Sci (2000) 1.19
Lipoprotein pigments--their relationship to ageing in the human nervous system. I. The lipofuscin content of nerve cells. Brain (1974) 1.19
The transcriptional factor LBP-1c/CP2/LSF gene on chromosome 12 is a genetic determinant of Alzheimer's disease. Hum Mol Genet (2000) 1.16
The relationship between lipofuscin pigment and ageing in the human nervous system. J Neurol Sci (1978) 1.16
A comparison of changes in the nucleus basalis and locus caeruleus in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1984) 1.15
Early senile plaques in Down's syndrome brains show a close relationship with cell bodies of neurons. Neuropathol Appl Neurobiol (1990) 1.15
The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry (1982) 1.15
A pathological study of the association between Lewy body disease and Alzheimer's disease. J Neurol Neurosurg Psychiatry (1989) 1.15
The selective vulnerability of nerve cells in Huntington's disease. Neuropathol Appl Neurobiol (2001) 1.14
Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. Neurology (2002) 1.14
Familial progressive aphasia: its relationship to other forms of lobar atrophy. J Neurol Neurosurg Psychiatry (1993) 1.12
Cytophotometric mapping of neuronal changes in senile dementia. J Neurol Neurosurg Psychiatry (1977) 1.11
Changes in nerve cells of the nucleus basalis of Meynert in Alzheimer's disease and their relationship to ageing and to the accumulation of lipofuscin pigment. Mech Ageing Dev (1984) 1.11
An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease. Neurobiol Aging (1987) 1.10
Pathological basis for neurotransmitter changes in Parkinson's disease. Neuropathol Appl Neurobiol (1983) 1.10
Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J Neurochem (1987) 1.09
The topography of plaques and tangles in Down's syndrome patients of different ages. Neuropathol Appl Neurobiol (1987) 1.09
Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect Immun (1999) 1.09
Neuromelanin and RNA in cells of substantia nigra. J Neuropathol Exp Neurol (1977) 1.08
Consequences of Hox gene duplication in the vertebrates: an investigation of the zebrafish Hox paralogue group 1 genes. Development (2001) 1.07
The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system. Mech Ageing Dev (1983) 1.06
A quantitative analysis of the incorporation of fibulin-1 into extracellular matrix indicates that fibronectin assembly is required. Matrix Biol (1995) 1.02
Loss of nerve cells from locus coeruleus in Alzheimer's disease is topographically arranged. Neurosci Lett (1986) 1.02
Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype. Arch Neurol (1995) 1.02
The topography of cell loss from locus caeruleus in Alzheimer's disease. J Neurol Sci (1986) 1.02
The effect of age and Alzheimer's disease on pyramidal neuron density in the individual fields of the hippocampal formation. Acta Neuropathol (1992) 1.00
Cognitive change in motor neurone disease/amyotrophic lateral sclerosis (MND/ALS). J Neurol Sci (2000) 1.00
Locus coeruleus cell loss in the aging human brain: a non-random process. J Comp Neurol (1995) 0.98
Alterations in protein synthetic capability of nerve cells in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1981) 0.98
The topographic distribution of senile plaques and neurofibrillary tangles in the brains of non-demented persons of different ages. Neuropathol Appl Neurobiol (1987) 0.98
Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech Ageing Dev (1983) 0.97
Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders. Hum Neurobiol (1986) 0.97
Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains. J Neuropathol Exp Neurol (1998) 0.97
Colocalization of lysosomal hydrolase and beta-amyloid in diffuse plaques of the cerebellum and striatum in Alzheimer's disease and Down's syndrome. J Neuropathol Exp Neurol (1996) 0.95
Monoaminergic neurotransmitter systems in presenile Alzheimer's disease and in senile dementia of Alzheimer type. Clin Neuropathol (1985) 0.95
The effects of ageing on the pigmented nerve cells of the human locus caeruleous and substantia nigra. Acta Neuropathol (1979) 0.95
Serglycin-binding proteins in activated macrophages and platelets. J Leukoc Biol (1996) 0.94
Phosphorylation of Tau proteins: a major event during the process of neurofibrillary degeneration. A comparative study between Alzheimer's disease and Down's syndrome. Brain Res (1990) 0.94
The DNA content of Purkinje cells in mammals. J Comp Neurol (1978) 0.94
Monoclonal antibodies to purified cortical Lewy bodies recognize the mid-size neurofilament subunit. Ann Neurol (1997) 0.94
Incorporation of cellular and plasma fibronectins into smooth muscle cell extracellular matrix in vitro. Proc Natl Acad Sci U S A (1985) 0.93
Is the loss of cerebral cortical choline acetyl transferase activity in Alzheimer's disease due to degeneration of ascending cholinergic nerve cells. J Neurol Neurosurg Psychiatry (1982) 0.92
Collagenase production by early and late passage cultures of human fibroblasts. Exp Gerontol (1989) 0.92
The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome. J Neurol Neurosurg Psychiatry (1989) 0.92
Quantitative changes in cerebral cortical microvasculature in ageing and dementia. Neurobiol Aging (1987) 0.92
The -48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Abeta load in brain. J Med Genet (2001) 0.91
Serotonin nerve cells in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1983) 0.91
Overexpression of s100beta in Down's syndrome: correlation with patient age and with beta-amyloid deposition. Neuropathol Appl Neurobiol (1999) 0.90
Hypothalamus and dementia. Lancet (1981) 0.90
The fine structure of the axonal torpedo in Purkinje cells of the human cerebellum. Neurol Res (1980) 0.89
Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age. J Ment Defic Res (1985) 0.89
Variations in melanin content with age in the human substantia nigra. Biochem Exp Biol (1977) 0.89
Isolation and characterization of a Mr = 38,000 protein from differentiating smooth muscle cells. J Biol Chem (1985) 0.89
Granulovacuolar degeneration in pyramidal cells of the hippocampus. Acta Neuropathol (1978) 0.89
Nerve cell protein metabolism and degenerative disease. Neuropathol Appl Neurobiol (1982) 0.89
Normal frontal cortex histology and immunohistochemistry in patients with motor neuron disease. J Neurol Neurosurg Psychiatry (1995) 0.87
The quantitative assessment of lipofuscin pigment, cytoplasmic RNA and nucleolar volume in senile dementia. Neuropathol Appl Neurobiol (1978) 0.86
Allelic variations in apolipoprotein E and prion protein genotype related to plaque formation and age of onset in sporadic Creutzfeldt-Jakob disease. Neurosci Lett (1995) 0.86
A quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer's disease. J Neurol Sci (1990) 0.86
Neurological disease and herpes simplex virus. An immunohistochemical study. Acta Neuropathol (1983) 0.86
Changes in Alzheimer's disease in the magnocellular neurones of the supraoptic and paraventricular nuclei of the hypothalamus and their relationship to the noradrenergic deficit. Clin Neuropathol (1985) 0.85
The site of the earliest lesions of Alzheimer's disease. N Engl J Med (1988) 0.85
Activated astrocytes display increased 5-HT2a receptor expression in pathological states. Exp Neurol (1999) 0.84
Neurofibrillary pathology and protein synthetic capability in nerve cells in Alzheimer's disease. Neuropathol Appl Neurobiol (1981) 0.84
Apolipoprotein E allelic frequencies in patients with lobar atrophy. Neurosci Lett (1995) 0.83